MODIFIELD OLIGONUCLEOTIDES IN TRIPLE HELIX FORMATION

Information

  • Research Project
  • 3493258
  • ApplicationId
    3493258
  • Core Project Number
    R43CA059020
  • Full Project Number
    1R43CA059020-01
  • Serial Number
    59020
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/1992 - 32 years ago
  • Project End Date
    12/31/1992 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    6/1/1992 - 32 years ago
  • Budget End Date
    12/31/1992 - 31 years ago
  • Fiscal Year
    1992
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/1/1992 - 32 years ago

MODIFIELD OLIGONUCLEOTIDES IN TRIPLE HELIX FORMATION

The primary goal of this study is to chemically refine a class of sequence- specific, DNA binding, triple helix-forming oligonucleotides (TFOs). the unique feature of these TFOs is that binding of the third strand to its duplex DNA target is pH independent and is stabilized by GGC and TAT triplets such that the preferred orientation places the bound TFO antiparallel with respect to more purine rich strand of the underlying duplex. Our initial studies with a 38 base long oligonucleotide (HIV38p), designed to bind to the promoter region in the long terminal repeat sequence of human immunodeficiency virus (HIV), indicated that HIV38p has a tendency to self-associate due to high G content. Subsequent studies with HIV38p have shown that substitution of G with 2'-deoxy-7- deazaguanosine residues reduces the self-association considerably. Thus, substitution of some or all guanine residues in HIV38p with selected guanine analogs may reduce or eliminate self-association and improve triplex formation. We now propose to prepare TFOs containing various levels of substitutions ranging from 10 to 50% with 2'-deoxy-7-deazaguanosine or 2'-deoxy-6- thioguanosine employing solid-phase phosphoramidite chemistry. The modified oligonucleotides thus obtained will be purified and adequately characterized. The ability of these novel TFOs to form stable triplexes will be evaluated using band shift analysis, DNase footprinting experiments, melting curves and CD measurements. It is hoped that such a substitution improves triple helix structure, reduces self-association, increases binding affinity and antiviral (HIV and HSV) activity. Detailed biological effects of such modified TFOs will be assessed in Phase II studies.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    393
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    TRIPLEX PHARMACEUTICAL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    THE WOODLANDS
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    77380
  • Organization District
    UNITED STATES